112 related articles for article (PubMed ID: 11306716)
1. Antimineralocorticoid 11beta-substituted spirolactones exhibit androgen receptor agonistic activity: a structure function study.
Nirdé P; Térouanne B; Gallais N; Sultan C; Auzou G
Mol Pharmacol; 2001 May; 59(5):1307-13. PubMed ID: 11306716
[TBL] [Abstract][Full Text] [Related]
2. A single amino acid mutation of ala-773 in the mineralocorticoid receptor confers agonist properties to 11beta-substituted spirolactones.
Auzou G; Fagart J; Souque A; Hellal-Lévy C; Wurtz JM; Moras D; Rafestin-Oblin ME
Mol Pharmacol; 2000 Oct; 58(4):684-91. PubMed ID: 10999937
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of spirolactone recognition by the mineralocorticoid receptor.
Huyet J; Pinon GM; Fay MR; Fagart J; Rafestin-Oblin ME
Mol Pharmacol; 2007 Sep; 72(3):563-71. PubMed ID: 17569793
[TBL] [Abstract][Full Text] [Related]
4. Mutation of the androgen receptor at amino acid 708 (Gly-->Ala) abolishes partial agonist activity of steroidal antiandrogens.
Terouanne B; Nirdé P; Rabenoelina F; Bourguet W; Sultan C; Auzou G
Mol Pharmacol; 2003 Apr; 63(4):791-8. PubMed ID: 12644579
[TBL] [Abstract][Full Text] [Related]
5. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands.
Marhefka CA; Moore BM; Bishop TC; Kirkovsky L; Mukherjee A; Dalton JT; Miller DD
J Med Chem; 2001 May; 44(11):1729-40. PubMed ID: 11356108
[TBL] [Abstract][Full Text] [Related]
6. Specific recognition of androgens by their nuclear receptor. A structure-function study.
Poujol N; Wurtz JM; Tahiri B; Lumbroso S; Nicolas JC; Moras D; Sultan C
J Biol Chem; 2000 Aug; 275(31):24022-31. PubMed ID: 10787411
[TBL] [Abstract][Full Text] [Related]
7. Antagonism in the human mineralocorticoid receptor.
Fagart J; Wurtz JM; Souque A; Hellal-Levy C; Moras D; Rafestin-Oblin ME
EMBO J; 1998 Jun; 17(12):3317-25. PubMed ID: 9628869
[TBL] [Abstract][Full Text] [Related]
8. Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12.
Cantin L; Faucher F; Couture JF; de Jésus-Tran KP; Legrand P; Ciobanu LC; Fréchette Y; Labrecque R; Singh SM; Labrie F; Breton R
J Biol Chem; 2007 Oct; 282(42):30910-9. PubMed ID: 17711855
[TBL] [Abstract][Full Text] [Related]
9. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure, docking study and structure-activity relationship of carborane-containing androgen receptor antagonist 3-(12-hydroxymethyl-1,12-dicarba-closo-dodecaboran-1-yl)benzonitrile.
Ohta K; Goto T; Fujii S; Kawahata M; Oda A; Ohta S; Yamaguchi K; Hirono S; Endo Y
Bioorg Med Chem; 2011 Jun; 19(11):3540-8. PubMed ID: 21536446
[TBL] [Abstract][Full Text] [Related]
11. A naturally occurring mutation in the human androgen receptor of a subject with complete androgen insensitivity confers binding and transactivation by estradiol.
Bonagura TW; Deng M; Brown TR
Mol Cell Endocrinol; 2007 Jan; 263(1-2):79-89. PubMed ID: 17011702
[TBL] [Abstract][Full Text] [Related]
12. The use of androgen receptor amino/carboxyl-terminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity.
Ghali SA; Gottlieb B; Lumbroso R; Beitel LK; Elhaji Y; Wu J; Pinsky L; Trifiro MA
J Clin Endocrinol Metab; 2003 May; 88(5):2185-93. PubMed ID: 12727974
[TBL] [Abstract][Full Text] [Related]
13. Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor.
Hellal-Levy C; Fagart J; Souque A; Wurtz JM; Moras D; Rafestin-Oblin ME
Mol Endocrinol; 2000 Aug; 14(8):1210-21. PubMed ID: 10935545
[TBL] [Abstract][Full Text] [Related]
14. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
[TBL] [Abstract][Full Text] [Related]
15. New naturally occurring missense mutations of the human mineralocorticoid receptor disclose important residues involved in dynamic interactions with deoxyribonucleic acid, intracellular trafficking, and ligand binding.
Sartorato P; Cluzeaud F; Fagart J; Viengchareun S; Lombès M; Zennaro MC
Mol Endocrinol; 2004 Sep; 18(9):2151-65. PubMed ID: 15192075
[TBL] [Abstract][Full Text] [Related]
16. Agonist and antimineralocorticoid activities of spirolactones.
Sakauye C; Feldman D
Am J Physiol; 1976 Jul; 231(1):93-7. PubMed ID: 183514
[TBL] [Abstract][Full Text] [Related]
17. Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively.
Shkolny DL; Beitel LK; Ginsberg J; Pekeles G; Arbour L; Pinsky L; Trifiro MA
J Clin Endocrinol Metab; 1999 Feb; 84(2):805-10. PubMed ID: 10022458
[TBL] [Abstract][Full Text] [Related]
18. Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor.
Quinkler M; Meyer B; Bumke-Vogt C; Grossmann C; Gruber U; Oelkers W; Diederich S; Bahr V
Eur J Endocrinol; 2002 Jun; 146(6):789-99. PubMed ID: 12039699
[TBL] [Abstract][Full Text] [Related]
19. Participation of critical residues from the extreme C-terminal end of the human androgen receptor in the ligand binding function.
Tahiri B; Auzou G; Nicolas JC; Sultan C; Lupo B
Biochemistry; 2001 Jul; 40(29):8431-7. PubMed ID: 11456479
[TBL] [Abstract][Full Text] [Related]
20. The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor.
Fagart J; Seguin C; Pinon GM; Rafestin-Oblin ME
Mol Pharmacol; 2005 May; 67(5):1714-22. PubMed ID: 15716462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
